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1. Introduction 
1.1 The field of kinins and their receptors  
Kinins are a group of bioactive peptides, which are formed by an endogenous enzymatic 
cascade consisting of precursor substrates called kininogens and the proteolytic kallikrein 
enzymes (kininogenases). So far, two kinin-releasing enzymes (kininogenases) have been 
characterized, plasma (hKB1/LKLB1) and tissue (hK1/KLK1) kallikreins (Fig. 1). Both 
enzymes are serine proteases that are found in glandular cells, neutrophils, and biological 
fluids. Kininogens are multifunctional proteins involved in cascade reactions during 
inflammation (Bhoola et al., 1992), and more recently in carcinogenesis (Bhoola et al., 1992; 
2001; Leeb-Lundberg et al., 2005). Kinins namely bradykinin (BK) and kallidin (Lys-BK) are 
among the most potent pro-inflammatory vasoactive peptides generated during tissue 
injury and noxious stimulation. BK and Lys-BK undergo metabolic degradation at a variable 
rate by amino-, carboxy- and endopeptidases found in tissues and biological fluids. The 
most physiologically relevant enzymes are carboxypeptidase N (from plasma) and 
carboxypeptidase M (from cell membranes), which remove the carboxy-terminal Arg 
present at end of the kinin molecule, resulting in the formation of the active metabolites des-
Arg9-BK (DBK) and des-Arg10-kallidin, known also as Lys-des-Arg9-BK (LDBK) (Fig. 1). 
Furthermore, neutral endopeptidase 24.11 (CD10, enkephalinase) and angiotensin I 
converting enzyme, act as dipeptidyl carboxypeptidases by removing the dipeptide Phe8-
Arg9 from the carboxy terminus end of BK or Lys-BK (Couture et al., 2004). It is important to 
mention that endopeptidase 24.15 and angiotensin I converting enzyme cleave the dipeptide 
Ser6-Pro7 from bradykinin 1-7 (BK1-7) to produce bradykinin 1-5 (BK1-5), one of the final 
metabolites of BK and DBK that possesses the longer half-life of this peptide family. The 
half-life of kinins depends on the rate and site of destruction, most rapid in the circulation, 
but less so in the extracellular fluid space and by cells. Actually, in plasma the half-life of BK 
and LDBK is short (15 to 20 sec) whereas BK1-5, considered in the past an inactive fragment, 
is considered to have a half-life of 86 to 101 min (Shima et al., 1992; Murphey et al., 2000; 
2006; Morinelli et al., 2002).  
Kinins are positively charged peptides that influence tissues and cells by stimulating two 
pharmacologically distinct G protein-coupled receptors (GPCRs). Kinin receptors are  
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Fig. 1. Major components of the kinin system. The kininogenases plasma and tissue 
kallikreins hydrolize either high or low molecular weight kininogens to release the kinin 
domain. Carboxypeptidases remove the Arg9 from bradykinin or Lys-bradykinin to 
generate B1 receptor agonists. 
situated on the plasma membranes of many cell types and are coupled principally to Gǂq 
and Gǂi, (Austin et al., 1997; Regoli et al., 2001). These receptors are designated as kinin B1 
(B1R) or B2 (B2R) receptors (Fig.1). B2R is a preformed receptor, widely distributed and 
activated by the parent molecules BK and Lys-BK. B1R is activated by DBK and LDBK, two 
kinins that lack the Arg9 at the carboxy-terminus of the parental BK or LBK molecule 
(Bhoola et al., 1992; 2001; Leeb-Lundberg et al., 2005). 
B1R is generally expressed at low levels in normal tissues, but is strongly up-regulated 
during inflammation, tissue injury, cancer, exposure to bacterial endotoxins such as 
lypopolysaccharide, growth factors (epidermal growth factor and endothelial growth factor) 
cytokines (principally interleukin-lǃ, interleukin-8 and tumor necrosis factor-ǂ) or even its 
own agonist, LDBK (Marceau et al., 1998; Yang et al., 2001). For this reason, there is an 
increase in the number of B1 binding sites in inflamed or carcinogenic tissue. Moreover, an 
up-regulation of the kinin B1R has been found in several tumors, immune-modulated 
disorders such as rheumatoid arthritis, transplant rejection, glomerulonephritis and in 
human fibrotic lung tissue. 
Additional differences between both types of kinin receptors reside in the fact that the B2R 
is internalized and extensively recycled to the cell surface by its agonist, whereas the B1R is 
up-regulated in inflammatory disorders and cancer, and its expression is controlled by 
signaling pathways such as stress mitogen-activated protein and nuclear factor kappa B 
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(NF-κB) (Marceau et al., 2002). In fact, sequence analyses show the presence of a 
transcriptional regulatory site for NF-κB in the promoter region of the B1R (Bachvarov et al., 
1996; Ni et al., 1998) a finding that may explain why expression of the B1R gene is tissue and 
cell specific (Yang et al., 2001).  
The different cell types in which expression and activation of kinin receptors has been 
determined include endothelial, epithelial and neural cells, smooth muscle cells, 
neutrophils, lymphocytes, monocytes, keratinocytes, chondrocytes and fibroblasts. 
Depending upon the cell type involved, kinin receptors activate different intracellular 
signaling pathways, which regulate processes such as, cell proliferation, differentiation, 
migration, vascular permeability, contraction of smooth muscle, excitation of nerve endings 
and release of a variety of biologically active secondary mediators. In this chapter, we will 
focus primarily on the most important signaling pathways triggered after B1R stimulation. 
2. Structure of kinin B1 receptor 
In general, the information on the structure of kinin receptors has been obtained by chemical 
cross-linking experiments, mutagenesis approaches, classical pharmacological assays, and 
studies with domain-specific anti-receptor antibodies (Prado et al., 2002; Blaukat, 2004). All 
these approaches have shown that B1R belongs to the GPCR family and that it is integrated 
into the plasma membrane. The amino-terminus end is exposed to the extracellular space 
and contains (three) consensus sites of the Asn-Xaa-Ser/Thr type for N-glycosilation and the 
most of them are clustered on their N-terminal domains. Is noteworthy that the kinin-
binding site is located at the amino-terminus end of the third extracellular loop. According 
to Kang et al.,(2005) the presence of multiple bands observed for the recombinant expressed 
human B1R is strongly reminiscent of patterns of the partially glycosylated B2R. However, a 
B1R in which the N-terminal domain had been truncated to remove putative N-
glycosylation sites migrated as a homogeneous specie (Kang et al., 2005). Furthermore, the 
treatment of the hemagglutinin-tagged human B1R, expressed in HEK293 cells, with N-
glycosidase F resulted in the conversion of the receptor from a heterogeneous specie 
migrating at 35 to 45 kDa to a relatively homogeneous one migrating at 37 kDa. We have 
observed a similar electrophoretic pattern of the B1R protein in human neutrophils 
(Ehrenfeld et al., 2006), breast cancer cells (Molina et al., 2009), endothelial cells and 
fibroblasts (our group, unpublished data). It is postulated that glycosylation probably 
increases the hydrophilicity of the extracellular portions of B1R affecting or regulating 
ligand affinity, efficient G protein coupling, maturation (folding, stabilization), intracellular 
trafficking and receptor oligomerization or receptor degradation (Menke et al., 1994; 
MacNeil et al., 1995; Leeb-Lundberg et al., 2005). Even more, it has been demonstrated that 
kinin-mediated mitogenic signaling and prostate cell growth is blocked by B1 and B2 
receptor antagonists indicating that these effects depend on both kinin receptors. These 
results provide evidence for the existence of B1R/B2R heterodimers in PC3 prostate cancer 
cells and demonstrate that antagonism of one receptor interferes with the ability of the 
other, possibly at the level of receptor-Gq protein coupling (Barki-Harrington et al., 2003). 
It is known that B1R can dimerize, oligomerize or heterodimerize with the B2R or other 
molecule. Actually, it is known that B1R heterodimerizes with membrane carboxypeptidase 
M, facilitating receptor signaling via carboxypeptidase M-mediated conversion of 
bradykinin or kallidin to a des-[Arg9]kinin. This critical interaction potentiates B1R signaling 
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and uncovers a new mode of GPCR activation by a cell surface peptidase (Zhang et al., 
2011). Therefore, it is clear that knowledge of the molecular structure has been important in 
determining B1R function. 
3. Classical signaling pathways activated by kinin B1 receptor 
In general, B1R activates most of the signaling pathways activated by B2R (reviewed by 
Marceau et al., 1998 and Leeb-Lundberg et al., 2005). Although both kinin receptors are 
coupled to similar signal transduction pathways, the differences in patterns of signaling are 
due to different degrees of short-term regulation that include both receptor desensitization 
and internalization (Leeb-Lundberg et al., 2005). The B2R is stable in the absence of its 
agonist, but it is rapidly desensitized after ligand stimulation by a mechanism that includes 
recruitment of -arrestin 2, internalization in a clathrin-dependent manner and recycling 
upon agonist treatment (Enquist et al., 2007). The B1R is not phosphorylated either under 
basal conditions or in response to agonist (Blaukat et al., 1999) and desensitizes slightly 
upon further stimulation with its agonist (Mathis et al., 1996). Actually, the B1R is 
constitutively internalized in the absence of agonist via a clathrin-dependent pathway, do 
not recruit -arrestin 2, bind G protein-coupled receptor sorting protein and go to lysosomes 
for degradation. Binding of agonist to the B1R inhibits its constitutive internalization 
thereby reducing the rate of spontaneous clearance of receptors from the cell membrane and 
at the same time delaying B1R degradation (Enquist et al., 2007). This behavior is according 
with B1R up-regulation by cytokines and other inflammatory stimuli that result in a high 
number of receptors on the cell surface, available for ligand binding (Fig. 2). 
 
Fig. 2. Regulation of B1R levels on the cell membrane. The B1R is constitutively internalized, 
but the number of B1R molecules on the cell membrane increases after binding of its ligand. 
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It is known that B1R can be coupled to different pathways according to the cell type 
involved. Signaling of the B1R results in the activation of protein kinase C (PKC) and 
tyrosine kinase cascades, coordinated with activation of the mitogen-activated protein 
kinase (MAPK) pathway and NF-B. B1R activation also stimulates phosphatidilinositol 
hydrolysis in smooth muscle cells leading to mobilization of intracellular Ca2+, 
phospholipase C or phospholipase A, and appears to induce biosynthesis and release of 
prostaglandins (Bhoola et al., 1992; 2001; Leeb-Lundberg et al., 2005). In vascular smooth 
muscle cells, B1R stimulation produces a significant dependence on extracellular Ca2+ and a 
transient increase in phosphatidilinositol hydrolysis that is more sustained than that 
generated by the B2R (Tropea et al., 1993). Nevertheless, in the rat renal cortical collecting 
duct cells, keratinocytes, breast cancer cells and neutrophils B1R does not induce 
intracellular Ca2+ mobilization (Ehrenfeld et al., 2006; Matus et al., 2008; Molina et al., 2009) 
Another characteristic of B1R is its capacity to regulate the cell cycle. In some cases, B1R is 
proliferative as seen in fibroblasts, vascular smooth muscle cells, estrogen-sensitive breast 
cancer cells, and this response involves MAPK activation (Marceau and Tremblay, 1986; 
Christopher et al., 2001; Molina et al., 2009). In vascular smooth muscle cells, B1R is induced 
only in response to injury, regulates proliferation by pathways that include activation of 
cholera toxin-sensitive Gǂq, PKC, Src kinase and MAPK. In estrogen-sensitive breast cancer 
cells, Molina et al.,(2009) showed that nanomolar concentrations of the B1R agonist produced 
an increase in BrdU incorporation as measured in a proliferation assay. The use of inhibitors of 
MEK, the kinase which phosphorylates ERK1/2 MAPK, such as PD98059 or UO126, decrease 
the phosphorylation of ERK1/2 and completely abolished the incorporation of BrdU. At the 
same time, we demonstrated that this effect was dependent on epidermal growth factor 
receptor (EGFR) transactivation because the use of AG1478 blunted the activation of this 
MAPK. In addition, we have observed the proliferative effect of B1R stimulation on MDA-MB-
231 estrogen-insensitive breast cancer cells (unpublished data). On the contrary, an 
antiproliferative effect has been observed in vascular smooth muscle cells, probably due to 
prolonged activation of MAPK and increased p27Kip1 activity (Dixon et al., 2002).  
Studies on the involvement of B1R in cell migration have shown that in primary cultures of 
arterial smooth muscle cells, activation of B1R inhibited cell migration, an effect that 
involves activation of PI3K, but not nitric oxide or prostanoid release (Morissette et al., 
2006). In contrast, activation of B1R induces the migration of human PC3 prostate cancer 
cells via activation of focal adhesion kinase (FAK), an important kinase involved in 
cytoskeletal reorganization and cell migration (Taub et al., 2003). On the other hand, studies 
performed in human neutrophils show that B1R stimulates leukocyte chemotaxis, though 
the pathways implicated in this process are still unknown (Ahluwalia & Perretti, 1996; 
Paegelow et al., 2002; Ehrenfeld et al., 2006). Moreover, it is known that release of the kinin 
moiety from kininogens sited on the neutrophil surface by enzymatic action of the classical 
tissue kallikrein (hK1) results in opening of junctions between the endothelial cells, thereby 
causing plasma extravasation (Stuardo et al., 2004). B1R modulates the release of matrix 
metalloproteases from both human neutrophils (Ehrenfeld et al., 2009) and breast cancer 
cells (Ehrenfeld et al., 2011), an event that may contribute to the extracellular matrix 
remodeling in processes such as inflammation, wound healing and cancer. Part of the effects 
produced by B1R in neutrophils and cancer cells include activation of ERK1/2 and p38 
MAPK and transactivation of EGFR in breast cancer cells, an event that usually results in the 
activation of MAPK. 
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Phosphorylation of a 125-kDa protein, following stimulation of B1R expressed in human 
keratinocytes was identified as FAK (Yurko et al., 2001; Matus et al., 2008). The activation 
of this kinase after stimulation of B1R has also been observed in immortalized HaCaT 
keratinocytes (unpublished data) and in human PC3 prostate cancer cells (Taub et al., 
2003). Moreover, we have shown that treatment of keratinocytes with herbimycin before 
stimulation with B1R agonists reduces FAK phosphorylation (Matus et al., 2008). Thus, it 
is likely that B1R activation may contribute to cell motility in several cell types. Another 
signaling pathway used by B1R includes activation of PKC. Overexposure of human 
keratinocytes to phorbol 12-myristate 13-acetate (PMA) or the preincubation with 
GF109203X, a potent and selective inhibitor of PKCs, demonstrated that phosphorylation 
of the EGFR was greatly reduced, corroborating the involvement of PKC (Matus et al., 
2008).  
4. Mechanisms of EGFR transactivation by kinin B1 receptor 
It is known that various stress factors such as ultraviolet light and ionizing radiation can 
activate receptor tyrosine kinases (RTKs), like EGFR, in the absence of ligand. Also, 
activation of GPCRs, like the B1R, can activate RTKs by a mechanism that has been called 
“transactivation” by Alex Ullrich's group (Daub et al., 1996). They found that several GPCR 
agonists were able to activate the EGFR that in turn acts as a signal transducer for GPCRs. 
The EGFR belongs to a family of type I RTKs that comprise four members: EGFR 
(ErbB1/HER1), ErbB2 (HER2/Neu), ErbB3 (HER3) and ErbB4 (HER4) (reviewed by 
Liebmann, 2011). Activation of these receptors occurs by dimerization after ligand binding 
or by high receptor density on the cell membrane. When the ligand binds to its receptor, it 
induces the formation of homo and heterodimers activating the intrinsic tyrosine kinase 
domain that results in phosphorylation of specific tyrosine residues forming part of the 
cytoplasmic receptor tail. These residues serve as docking sites for a variety of signaling 
molecules (Endoh et al., 2009). Overexpression of EGFR is an indication of poor prognostic 
in multiple tumor types. EGFR autophosphorylation in sites such as Tyr845 are directly 
phosphorylated by Src kinase family (Wetzker & Böhmer, 2003) and GPCR agonists induce 
activation of Src, which directly phosphorylates EGFR by ligand-independent pathways 
(Biscardi et al., 1999; Tice et al., 1999). Furthermore, phosphorylation of EGFR at Tyr845 in 
the kinase domain is implicated in stabilizing the activation loop, maintaining the active 
state enzyme, and providing a binding surface for substrate proteins among which are the 
MAPK pathways (Cooper & Howell, 1993; Hubbard et al., 1994). EGFR and cytoplasmic 
tyrosine kinase c-Src cooperate in several cellular functions such as proliferation and 
apoptosis. Boerner et al.,(2005) showed that c-Src-dependent phosphorylation of Tyr845 of 
EGFR is required for the DNA synthesis induced by activation of some G protein-coupled 
receptors in murine fibroblasts and breast cancer cells. The role of Tyr845 in DNA synthesis 
and cell proliferation was demonstrated by the microinjection of phosphoTyr845-containing 
peptide in these cells, which was able to ablate EGF-stimulate S-phase entry in both cell 
systems. This finding suggests that this residue is an important regulator of DNA synthesis 
induced by mitogens like EGF. Sato et al., (2003) using A431 carcinoma cells demonstrated 
that the expression of adaptor protein p52shc, or stimulation with EGF or H2O2 leads to 
phosphorylation of EGFR on Tyr845. Phosphorylation in this residue was inhibited by PP2, 
but not by AG1478, and is associated with Src activation and phosphorylation of activators 
of transcription type 3 and 5 (STAT 3/5). This effect was inhibited by introduction of an 
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antibody against phosphorylated Tyr845 or by transfection of a dominant-negative for c-Src 
into the cells. Moreover, the co-incubation of puried c-Scr and EGFR leads to 
phosphorylation of Tyr845 in vitro. Altogether, these results demonstrate that c-Src can 
directly phosphorylate EGFR on Tyr845. Similarly, different cell lines and animal studies 
have shown that MAPK and signal transducers like STAT-3 are important mediators of 
EGFR signaling after phosphorylation of different tyrosine residues in liver cells and 
hepatocellular carcinoma. Interestingly, it has been shown that homogenates of 
hepatocellular carcinomas present phosphorylation at Tyr845, but no EGFR 
phosphorylation at Tyr998, Tyr1045 or Tyr1068 (Kannangai et al., 2006). On the other hand, 
the SH2 domain of PLCǄ binds at phospho-Tyr992, resulting in activation of PLCǄ-mediated 
downstream signaling (Emlet et al., 1997). Phosphorylation of this residue was 
demonstrated in 38 of the 39 cases of esophageal carcinomas by inmunohistochemistry with 
an anti-phosphoTyr992-EGFR antibody (Miyawaki et al., 2008). Immunoreactivity to 
phosphorylated Tyr992 was mainly associated with areas of severe dysplasia and 
microinvasive foci adjacent to invasive carcinoma, suggesting a role of phosphorylated 
Tyr992-EGFR in invasion. Moreover, phosphorylation of Tyr992, in responses of ionizing 
radiation in chinese hamster ovary or A431 cells, is related to activation of PLCǄ and 
increases when the phosphatase SHP2 is blocked (Sturla et al., 2005). 
Phosphorylation of EGFR at Tyr1045 creates a major docking site for c-Cbl, an adaptor 
protein that leads to receptor ubiquitination and degradation following EGFR activation 
(Levkowitz, et al.,1999; Ettenberg, et al.,1999). The GRB2 adaptor protein binds activated 
EGFR at phospho-Tyr1068 (Rojas et al., 1996). Interestingly, Yamauchi et al.,(1998) 
demonstrated that binding of growth hormone to its receptor, which belongs to the cytokine 
receptor superfamily, activates Janus kinase tyrosine kinase, STAT proteins and MAPK that 
regulate expression of c-fos. This activation depends on phosphorylation of Tyr1068 by 
Janus kinase tyrosine kinase 2, providing docking sites for Grb2 and Shc protein adaptor 
and activating MAPK and gene expression. Phosphorylated Tyr1148 and Tyr1173 provide a 
docking site for the Shc scaffold protein and induce MAPK activation (Zwick, et al.,1999). 
Phosphorylation of these tyrosine residues is a key step for signaling activation and 
inhibition of intrinsic tyrosine kinase activity by highly potent and selective inhibitors such 
as AG1478 (tyrphostin), that block receptor phosphorylation and the subsequent signaling 
pathways triggered by EGFR (Fig. 3). 
In several cell types, the EGFR transactivation induced by GPCRs is mediated by the release 
of EGFR ligands such as heparin-binding EGF-like growth factor (HB-EGF), transforming 
growth alpha (TGF-) and/or amphiregulin (Fig. 3). These ligands are generated by 
activation of the ADAM family (a disintegrin and metalloprotease) of zinc-dependent 
metalloproteases. Members of the ADAM family like ADAM10, ADAM12 and ADAM17 
mediate GPCR-induced EGFR transactivation in different cell types (reviewed by Rozengurt 
et al., 2007). The mechanism by which members of the ADAM family are activated has been 
suggested to depend on the GPCR and the cell type involved. Activation can be through 
reactive oxygen species, PKC and Src, PI3K or ERKs (review by Ohtsu et al., 2006; 
Lemjabbar-Alaoui er al, 2011; Maretzky et al., 2011; Sun et al., 2010). In addition, different 
reports indicate that the use of Src inhibitors such as PP2 and GM6001, a broad spectrum 
metalloprotease inhibitor, partially block the MAPK or Akt pathways (Chen et al.,  
2011; Cramer et al., 2001; Mugabe et al., 2010; Stirnweiss et al., 2006) suggesting that  
GPCRs do not necessarily transactivate the EGFR to activate signaling pathways. Through  
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Fig. 3. Schematic representation of EGFR transactivation by a GPCR like the B1R. 
Stimulation of the B1R by its natural agonist may trigger specific signaling pathways and 
also produce activation of matrix metalloproteases (MMP-8, ADAM17) to release 
membrane-bound proligands that after being released will stimulate the EGFR. Stimulation 
of B1R also results in c-Src phosphorylation that may in turn produce phosphorylation of 
specific tyrosine residues (Tyr845, Tyr992, Tyr1068) of EGFR. Phosphorylation of other 
tyrosine residues such as Tyr1045, Tyr1148 and Tyr1173 has not been yet described. 
Transactivation of EGFR is used by the B1R to activate specific signaling pathways like p38, 
ERK1/2 and JNK MAPK. PLC, Phospholipase C. 
transactivation, GPCRs can regulate cell growth, cell differentiation, survival and migration 
and play important roles in pathophysiological processes such as embryo development, 
wound healing and cancer progression. 
Few studies have considered the transactivation of EGFR by either kinin B1 or B2 receptors. 
Studies performed in different cell types show that B2R activation triggers EGFR 
transactivation. The phosphorylation of ERK1/2 MAPK, produced by stimulation of COS-7 
cells with a B2R agonist involves the independent activation of PKC and EGFR 
transactivation (Adomeit et al., 1999). Similar results in keratinocytes and renal IMCD-3 cells 
show that MAPK phosphorylation was partially and completely dependent on EGFR 
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transactivation, respectively (Mukhin et al., 2006 and Vidal et al., 2005). It has been shown 
that bradykinin can produce activation of p60Src and Src-dependent phosphorylation on 
Tyr845 of EGFR as well as recruitment of PLC in primary cultures of rat adrenal chromaffin 
cells and PC12 cells (Hur et al., 2004). Moreover, Yang et al., (2005) demonstrated, using 
Western blot and [3H]thymidine incorporation, that bradykinin induces proliferation of 
vascular smooth muscle cells mediated, at least in part, through activation of kinases of the 
Src family, EGFR transactivation, and PI3K-AKT pathways. Studies directed to elucidate the 
transactivation mechanism induced by B2R have shown that depending on the cell type, 
involve ADAM17 or metalloprotease 8 to cleave EGFR ligands (Dey et al., 2010; Methner et 
al., 2009). Reports regarding these events and the B1R are scarce. Matus et al., (2008) showed 
that stimulation of the kinin B1R in human keratinocytes produced the phosphorylation of 
tyrosine residues in a protein with a molecular mass of 170 kDa, that was later identified as 
EGFR. In these cells, the B1R induces the phosphorylation of Tyr845, Tyr992 and Tyr1068 
residues on the EGFR molecule, an effect that was blocked by AG1478, a specific inhibitor of 
the EGFR tyrosine kinase activity. Similar results were obtained in the HaCaT keratinocyte 
cell line when EGFR transactivation by the B1R was analyzed (Matus et al., unpublished 
data). 
Studies performed on estrogen-sensitive breast cancer cells strongly suggest that the 
proliferative effect induced by the B1R depends on the activity of EGFR and subsequent 
ERK1/2 MAPK phosphorylation (Molina et al., 2009). We have also reported that release of 
metalloproteases in MCF-7 and MDA-MB-231 breast cancer cells was blocked by AG1478, an 
observation that was confirmed by transfection of breast cancer cells with the dominant 
negative EGFR mutant HERCD533 (Ehrenfeld et al., 2011). The transactivation mechanism 
involved in EGFR activation by B1R agonists has not been elucidated yet, but work performed 
by our group in human HaCaT keratinocytes, MCF-7 breast cancer cell has visualized that B1R 
stimulation produces Src phosphorylation, that is blocked by the specific Src inhibitor, PP2 
(Figs. 4 and 5). Interestingly, Src phosphorylates specifically the Tyr845 residue present in the 
active site of EGFR, therefore when we inhibited Src activity, phosphorylation of EGFR in 
Tyr845 was also inhibited (our group, unpublished data (Fig. 3). 
5. Potential usefulness of currently available kinin antagonists and kinase 
inhibitors in pathological processes 
The importance of kinin receptors, especially the B1R, is illustrated by many publications 
that demonstrate their involvement in different pathological processes such as cancer, and 
especially breast cancer as mentioned early in the text. From a functional point a view, both 
B1 and B2 receptors are central players in the aetiology of pain, inflammation and cancer. 
Thus, the use of antagonists or inhibitors directed to specific intracellular pathways may be 
a useful approach to understand the mechanisms of particular pathological processes and 
then to promote them as useful pharmacological agents. Frequently, B2R is associated with 
the acute phase of inflammation and noniception, whereas the B1R after its up-regulation by 
inflammatory mediators is more relevant during chronic or persistent inflammation. For this 
reason, the use of antagonists of both peptidic and non-peptidic nature or blockade of kinase 
pathways triggered by activation of kinin receptors may become important clinical tools for 
treatment of persistent inflammation, cancer and pain, especially when no other therapy is 
available or provides beneficial effects (Campos et al., 2006).  
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Fig. 4. The kinin B1R stimulation triggers transactivation of EGFR in estrogen-insensitive 
(MDA-MB-231) and estrogen-sensitive (MCF-7) breast cancer cells. Cells were cultured in 
DMEM-F12 or DMEM without phenol red, synchronized for 24 h and then stimulated with 10 
nM Lys-des[Arg9]bradykinin for different periods of time. When stimulation was completed, 
the cells were homogenized in the presence of protease inhibitors, proteins separated by 
polyacrylamide gel electrophoresis and then transferred to immobilon membranes. 
Representative Western blots performed with a monoclonal antibody that detects 
phosphorylation on Tyr845 residue of the EGFR are shown. AU, arbitrary intensity units. 
IL-4 is a cytokine with an important role in asthma and chronic obstructive pulmonary 
disease that promotes eosinophilic inflammation and mucus hypersecretion. In this regard, 
Bryborn et al.,(2004) demonstrated that long-term exposure to IL-4 increases contractile 
response of bronchial smooth muscle induced by B1 or B2 receptor agonists. This effect 
appears to be mediated via an up-regulation of B1R and MAPK pathways since the pre-
treatment with SP600125, a c-Jun N-terminal kinase inhibitor or SB203580, a p38 MAPK 
inhibitor or PD98059, an inhibitor of ERK1/2 MAPK phosphorylation, inhibited that response. 
Similarly, IL-1ǃ induces the up-regulation of B1R and B2R in mouse tracheal smooth muscle 
and increases the contractile responses induced by the respective kinin agonists (Zhang et al., 
2007a). The effect was inhibited by SP600125 and TAT-TI-JIP, two JNK inhibitors, but not by 
inhibitors of ERK1/2 MAPK pathways (Zhang et al., 2007b). The importance of B1R in 
inflammatory reactions was also investigated by the group of Lin et al.,(2010) who 
demonstrated the involvement of B1R in cigarette smoke-induced airway inflammation by a 
mechanism that includes the participation of IL-1ǃ. In fact, rat lung slices treated with total 
particulate matter of cigarette smoke for 24 h showed an enhanced expression of B1R and IL-
1ǃ. At the same time, Xu et al.,(2010) reported that nicotine induces airway 
hyperresponsiveness via transcriptional up-regulation of B1R and B2R and activation of JNK, 
but not ERK1/2 or p38 MAPK. The use of SP600125 a specific JNK inhibitor and  
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Fig. 5. Stimulation of the kinin B1R triggers transactivation of EGFR in human HaCaT 
keratinocytes. The epidermal cells were pre-incubated with 1 μM of AG1478 for 30 min or 
directly stimulated with 100 nM Lys-des[Arg9]bradykinin for 15 min or 2.5 ng/ml EGF for 
10 min. Proteins were separated by polyacrylamide gel electrophoresis and Western blots 
were performed using a monoclonal antibody that detects phosphorylation on Tyr845 
residue of the EGFR molecule. A representative experiment is shown. AU, arbitrary 
intensity units. 
YM976 a specific phosphodiesterase inhibitor abolished the nicotine-induced effects on kinin 
receptor-mediated contractions and reverted the enhanced receptor mRNA expression. Other 
reports demonstrate that the increased expression of B1R relays on oxidative stress, IL-1ǃ and 
NF-κB, but not on cyclooxygenase or TNF-ǂ. These results were obtained using the human 
alveolar epithelial A549 cell line treated with particulate matter. The increase of B1R mRNA 
was prevented by co-treatments with N-acetyl-l-cysteine (a potent antioxidant), 
diphenyleneiodonium (NADPH oxidase inhibitor), IL-1Ra (IL-1 receptor antagonist) and SN-
50 (specific inhibitor of NF-κB activation), but not by pentoxifylline (TNF-ǂ release inhibitor), 
indomethacin and niflumic acid (COX-1 and 2 inhibitors)(Talbot et al., 2011).  
In the skin, the mRNAs for hK1 tissue kallikrein and B1R have been reported in both normal 
human skin and in biopsies of patients with some skin diseases (Schremmer-Danninger et 
al.,1995; 1998; 2004; Matus et al.,2008; Pietrovski et al., 2009). Furthermore, the expression of 
B1R mRNA and protein has been demonstrated in keratinocytes of normal human 
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epidermis, in primary cultures and in the immortalized HaCaT cell line (Matus et al.,2008). 
Additionally, the expression of B1R in skin may be enhanced when this organ is exposed to 
many noxious agents present in our environment. In cutaneous models of inflammation 
developed in mice, peptidic and non-peptidic kinin receptor antagonists have been effective 
in reducing cutaneous neurogenic inflammation (Pietrovski et al., 2009). Recently, Pietrovski 
et al.,(2011) demonstrated that both B1R and B2R participate in the hyperproliferative and 
inflammatory responses of mouse skin suggesting that the use of kinin receptor antagonists 
may be useful in the treatment of some skin disorders. 
Another disease in which the role of B1R has been considered is diabetes. Dias & Couture 
(2011) used the B1R antagonist, SSR240612 in a rat model of diabetes and insulin resistance, 
based on the hypothesis that B1R activates signaling pathways that lead to increased 
oxidative stress and promote insulin resistance (Dias et al., 2010). The use of such an 
experimental design reversed the effects of glucose on the expression of IL-1ǃ, TNF-ǂ, and 
macrophage CD68 that are linked to the deposition of adipose tissue. Given the association 
between chronic inflammation and insulin resistance, inhibition of B1R activity may 
contribute to increase sensitivity to insulin and to prevent obesity. In general, diabetes 
induces sensory polyneuropathy associated with pain (allodynia and termal hyperalgesia), 
conditions that are difficult to treat. For this reason, Dias et al.,(2007) tested the non-peptide 
and orally active B1R antagonist SSR240612 in a rat model of insulin resistance and tactile 
cold allodynia. Their results are the first to associate the B1R with allodynia, pain that was 
alleviated by treatment with SSR240612, probably by direct inhibition of B1R affecting the 
spinal cord and/or afferent sensory nerve excitation. Hawkinson et al.,(2007) probed other 
B1R antagonist named benzamide B1R antagonist 7-chloro-2-[3-(9-pyridin—4-yl-3,9-diaza-
spiro[5.5]undecanecarbonyl)phenyl]-2,3-dihydro-isoindol-1-one (ELN441958). This 
antagonist reduces in a dose-dependent manner the carrageenan-induced thermal 
hyperalgesia in a rhesus monkey tail-withdrawal model. 
In renal disease, B1R has been associated with tissue inflammation and renal fibrosis. Focal 
and segmental glomeruloesclerosis is one of the most important causes of end-stage renal 
failure and up-regulation of B1R in podocyte injury has been demonstrated by Pereira et 
al.,(2011). Despite this report, there are not additional studies that examine the use of specific 
antagonists or inhibitors for specific signaling pathways activated by the B1R in this disease. 
Respect to the participation of the kinin B1R in cancer, only a few reports indicates the 
importance of interrupting its intracellular signaling; the major efforts have been orientated to 
the B2R. Thus, many studies have tried to elucidate the importance of B2R in cancer and the 
consequence of using specific antagonists to reduce cell proliferation, enhance apoptosis or 
decrease the secretion of metalloproteases (Chan et al., 2002; Stewart et al.,2002; 2003; 2005; 
Jutras et al., 2010; Wang et al., 2010). Although one of these studies demonstrate that both 
PGE2 and BK stimulate invasion of head and neck squamous carcinoma cells via EGFR, the 
treatment of these cells with the B2R antagonist CU201 resulted in growth inhibition (Thomas 
et al., 2006). The combination of CU201 with the EGFR small-molecule inhibitor erlotinib 
resulted in additive inhibitory effects on cell growth in the same type of cells in vitro. 
6. Conclusion 
Despite the high number of reports demonstrating the involvement of B1R in the regulation 
of various diseases, studies on the use of specific kinin antagonists and/or kinase inhibitors 
www.intechopen.com
 
Signaling Pathways Coupled to Activation of the Kinin B1 Receptor 
 
121 
as potential therapeutic drugs has been limited. Therefore, further validation of kinin 
receptors as important therapeutic targets is crucial. Even though EGFR tyrosine kinase 
inhibitors such as erlotinib and gefitinib interfere with ATP binding and have been used in 
clinical trials, inhibiting tyrosine kinase activity and subsequently inhibiting signal 
transduction pathways triggered by EGFR such as MAPK, PI3K/Akt, STAT and PLC/PKC. 
Activation of these pathways also influences cell proliferation, survival and the metastatic 
potential of tumor cells. Others EGFR tyrosine kinase inhibitors (PD15035, AG1478 and PKI 
166) have been tested in animal model as mice with Type 2 Diabetic, mice with high-fat diet-
fed or rats with diabetic nephropathy. Results of experiments indicate that these inhibitors 
restore ischemia-induced neovascularization and blood flow recovery in type 2 diabetic 
mice, improves glucose tolerance, insulin sensitivity and reduces subclinical inflammation 
in high-fat diet-fed mice and attenuates the development diabetic nephropathy in rats. 
(Advani et al., 2011; Choi et al., 2011; Prada et al., 2009). 
Despite the success of inhibitors reported in clinical trials, some patients still develop 
resistance to anti-EGFR therapy. In addition, there are two mutations of EGFR that have 
been described. Mutations of the exon coding for tyrosine kinase domain (18 to 21) and 
truncating mutations (exons 2 to 7) that involves signaling pathways. The first group of 
mutations is involved in the failure of tyrosine kinase inhibitors whereas the second group 
of mutation leads to resistance of drugs (Colabufo, 2011). However, an alternative approach 
for overcoming resistance may be to simultaneously target additional pathways such as 
VEGF/VEGFR, and/or inhibit parallel signaling pathways that complement those activated 
by EGFR (e.g., mesenchymal-epithelial transition factor and mTOR) (Giaccone & Wang, 
2011) and we suggest, by the evidence expose in this chapter, may include the B1R, or B2R. 
Furthermore, understanding of the intracellular signaling pathways initiated by kinin 
receptors linked to EGFR and their involvement in the causation and progression of most 
human neoplasias (e.g., non-small cell lung cancer, colorectal cancer, glioblastoma, breast 
cancer and squamous cell carcinomas) suggests that these signaling pathways could be used 
as targets for development of novel drugs that inhibit EGFR activation. Currently there are 
insufficient studies on the inhibition of EGFR transactivation triggered by B1R to elucidate 
whether the interaction between EGFR and B1R could provide novel molecular agents for 
prevention or treatment of human cancer. 
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